DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc. is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations. The company’s product portfolio includes commercially marketed systems—most notably its G6 and G7 families—which are intended to simplify sensor insertion, extend wearable life and improve ease of use. These systems are used in both personal and professional settings, including by patients at home and by clinicians who monitor glucose remotely.

DexCom’s CGM ecosystem emphasizes connectivity and interoperability. Its devices support mobile apps for real-time glucose display and data sharing with caregivers, and are designed to integrate with insulin delivery systems and other digital health platforms to enable automated or guided diabetes management workflows. The company also invests in software and data analytics to enhance actionable insights for users and providers.

Operating commercially in the United States and across multiple international markets, including Europe and parts of the Asia‑Pacific region, DexCom pursues expanded access through reimbursement initiatives, partnerships and regulatory approvals. The company has emphasized ongoing research and development aimed at improving sensor accuracy, user convenience and the broader clinical applications of continuous glucose monitoring. It is led by CEO Kevin Sayer and a management team focused on device innovation and global commercial growth.

Key Stats

• Today's Range: $71.31 to $73.05
• 50-Day Range: $57.56 to $72.10
• 52-Week Range: $54.11 to $89.98
• Volume: 6.73 million shs
• Average Volume: 7.01 million shs
• Market Capitalization: $27.82 billion
• P/E Ratio: 30.81
• Dividend Yield: N/A
• Price Target: $82.21
• Consensus Rating: Moderate Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 84% of companies evaluated by MarketBeat, and ranked 93rd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 19 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

DexCom has a consensus price target of $82.21, representing about 14.0% upside from its current price of $72.10.

Amount of Analyst Coverage

DexCom has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 17.51%

Earnings Growth

Earnings for DexCom are expected to grow by 17.51% in the coming year, from $2.57 to $3.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 30.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 30.81, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 9.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.76% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 3.96, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently increased by 20.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.82

News Sentiment

DexCom has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for DexCom this week, compared to 12 articles on an average week.

Search Interest

27 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 93% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $379,990.00 in company stock.

Percentage Held by Insiders

0.28% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/23/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:DXCM
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 11,000
• Year Founded: 1999

Price Target and Rating

• Average Price Target for DexCom: $82.21
• High Price Target: $102.00
• Low Price Target: $64.00
• Potential Upside/Downside: +14.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.34
• Trailing P/E Ratio: 30.81
• Forward P/E Ratio: 28.05
• P/E Growth: 1.19
• Net Income: $836.30 million
• Net Margins: 19.31%
• Pretax Margin: 24.98%
• Return on Equity: 33.33%
• Return on Assets: 13.19%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 1.95
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $4.66 billion
• Price / Sales: 5.97
• Cash Flow: $2.77 per share
• Price / Cash Flow: 26.04
• Book Value: $7.66 per share
• Price / Book: 9.41

Miscellaneous

• Outstanding Shares: 385,870,000
• Free Float: 384,793,000
• Market Cap: $27.82 billion
• Optionable: Optionable
• Beta: 1.40